About BioSymetrics

90 percent of clinical trials fail before a drug can make it to patients, most due to lack of efficacy against the selected target. Biology is complex and reductionist approaches fail.

To better address this complexity, BioSymetrics takes an AI-driven approach to target discovery and precision medicines. We connect disease phenotype and genotype data between humans and model systems, use machine learning to make predictions, and couple that with high-content in vivo validation of new targets.